BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37353349)

  • 21. [Clinical analysis in a cohort of 102 patients with myelodysplastic syndrome characterized by erythroid hyperplasia].
    Yu Y; Sun AN; Chen SN; Wang QR; Zhang TT; Wu DP
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):29-33. PubMed ID: 28056320
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes.
    Xiong H; Yang XY; Han J; Wang Q; Zou ZL
    Braz J Med Biol Res; 2015 Mar; 48(3):207-13. PubMed ID: 25608238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review.
    Ganguly BB; Dolai TK; De R; Kadam NN
    J Cancer Res Ther; 2016; 12(3):1203-1206. PubMed ID: 28054536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Somatic Mutations of Acquired Aplastic Anemia].
    Zhang ML; Chen WS; Han B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Jun; 44(3):491-496. PubMed ID: 35791949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemogram and bone marrow morphology in children with chronic aplastic anemia and myelodysplastic syndrome.
    Wen JQ; Feng HL; Wang XQ; Pang JP
    World J Pediatr; 2008 Feb; 4(1):36-40. PubMed ID: 18402250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Childhood myelodysplastic syndrome.
    Chatterjee T; Choudhry VP
    Indian J Pediatr; 2013 Sep; 80(9):764-71. PubMed ID: 23912822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The current perspective of low-grade myelodysplastic syndrome in children.
    Hasegawa D
    Int J Hematol; 2016 Apr; 103(4):360-4. PubMed ID: 26939774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Pathogenesis of MDS.
    Look AT
    Hematology Am Soc Hematol Educ Program; 2005; ():156-60. PubMed ID: 16304374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
    Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
    Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
    Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
    Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
    Mangi MH; Mufti GJ
    Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
    Frietsch JJ; Dornaus S; Neumann T; Scholl S; Schmidt V; Kunert C; Sayer HG; Hochhaus A; La Rosée P
    Eur J Haematol; 2014 Sep; 93(3):247-59. PubMed ID: 24635656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA).
    Koh Y; Lee HR; Song EY; Kim HK; Kim I; Park S; Park MH; Kim BK; Yoon SS; Lee DS
    Leuk Res; 2010 Oct; 34(10):1344-50. PubMed ID: 20427085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.